TY - JOUR
T1 - Replacement of glucose with N-acetylglucosamine in peritoneal dialysis fluid - Experimental study in rats
AU - Breborowicz, Andrzej
AU - Pawlaczyk-Kuzlan, Malgorzata
AU - Pawlaczyk, Krysztof
AU - Baum, Ewa
AU - Tam, Paul
AU - Wu, George
PY - 2001
Y1 - 2001
N2 - ◆ Background: Glucose is still used as an osmotic solute in peritoneal dialysis fluids, despite evidence of its local (peritoneal) and systemic toxicities. However a constant search is underway for a new, more biocompatible osmotic solute for peritoneal dialysis fluids. ◆ Objective: The present study evaluated N-acetylglucosamine (NAG) in a concentration of 220 mmol/L as an alternative to glucose for the osmotic solute in peritoneal dialysis fluid, during chronic peritoneal dialysis in rats. ◆ Methods: For 8 weeks, male Wistar rats were infused with glucose-based or NAG-based dialysis fluid. Intraperitoneal inflammation and peritoneal permeability and morphology were evaluated in all rats during the study. ◆ Results: Repeated intraperitoneal infusion of the NAG-based dialysis fluid resulted in a weaker intra-abdominal inflammatory reaction as compared with the reaction in rats infused with glucose-based dialysis solution. At the end of the study, the concentration of hyaluronan in the peritoneal interstitium obtained from NAG-treated rats was higher than that found in the interstitium taken from animals exposed to dialysis fluid containing glucose. Also, peritoneal permeability to total protein was lower in NAG-treated rats. ◆ Conclusion: As an alternative to glucose, NAG used for the osmotic solute in peritoneal dialysis solution decreases the intraperitoneal inflammatory reaction induced by the process of peritoneal dialysis and, indirectly (owing to the increased hyaluronan content in the peritoneal interstitium), diminishes peritoneal permeability to protein.
AB - ◆ Background: Glucose is still used as an osmotic solute in peritoneal dialysis fluids, despite evidence of its local (peritoneal) and systemic toxicities. However a constant search is underway for a new, more biocompatible osmotic solute for peritoneal dialysis fluids. ◆ Objective: The present study evaluated N-acetylglucosamine (NAG) in a concentration of 220 mmol/L as an alternative to glucose for the osmotic solute in peritoneal dialysis fluid, during chronic peritoneal dialysis in rats. ◆ Methods: For 8 weeks, male Wistar rats were infused with glucose-based or NAG-based dialysis fluid. Intraperitoneal inflammation and peritoneal permeability and morphology were evaluated in all rats during the study. ◆ Results: Repeated intraperitoneal infusion of the NAG-based dialysis fluid resulted in a weaker intra-abdominal inflammatory reaction as compared with the reaction in rats infused with glucose-based dialysis solution. At the end of the study, the concentration of hyaluronan in the peritoneal interstitium obtained from NAG-treated rats was higher than that found in the interstitium taken from animals exposed to dialysis fluid containing glucose. Also, peritoneal permeability to total protein was lower in NAG-treated rats. ◆ Conclusion: As an alternative to glucose, NAG used for the osmotic solute in peritoneal dialysis solution decreases the intraperitoneal inflammatory reaction induced by the process of peritoneal dialysis and, indirectly (owing to the increased hyaluronan content in the peritoneal interstitium), diminishes peritoneal permeability to protein.
KW - Inflammation
KW - N-acetylglucosamine
UR - http://www.scopus.com/inward/record.url?scp=0035571598&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035571598&partnerID=8YFLogxK
U2 - 10.1177/089686080102103s69
DO - 10.1177/089686080102103s69
M3 - Article
C2 - 11887857
AN - SCOPUS:0035571598
SN - 0896-8608
VL - 21
SP - S365-S367
JO - Peritoneal Dialysis International
JF - Peritoneal Dialysis International
IS - SUPPL. 3
ER -